{"commentary":{"count":74,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":41,"podcast":33},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05445778\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"GLORIOSA","nct_id":"NCT05445778","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=gloriosa-nct05445778. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"GLORIOSA","arms":[{"description":"Mirvetuximab Soravtansine (MIRV) plus Bevacizumab","label":"Arm 1","type":"EXPERIMENTAL"},{"description":"Bevacizumab monotherapy","label":"Arm 2","type":"ACTIVE_COMPARATOR"}],"collaborators":["GOG Foundation"],"completion_date":{"date":"2032-05","type":"ESTIMATED"},"conditions":["Ovarian Cancer","Peritoneal Cancer","Fallopian Tube Cancer"],"enrollment":{"count":520,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Mirvetuximab soravtansine plus Bevacizumab","type":"DRUG"},{"name":"Bevacizumab","type":"DRUG"}],"last_update":"2026-06-02","lead_sponsor":"AbbVie","official_title":"Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Assess Progression-free survival (PFS)","timeFrame":"Up to 4 years"}],"references":[{"citation":"O'Malley DM, Myers T, Wimberger P, Van Gorp T, Redondo A, Cibula D, Nicum S, Rodrigues M, Backes FJ, Barlin JN, Lewin SN, Lim P, Pothuri B, Diver E, Banerjee S, Lorusso D. Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRalpha-high platinum-sensitive ovarian cancer. Future Oncol. 2024;20(32):2423-2436. doi: 10.1080/14796694.2024.2372241. Epub 2024 Jul 31.","pmid":"39082675","type":"DERIVED"}],"start_date":{"date":"2023-03-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer","url":"https://clinicaltrials.gov/study/NCT05445778"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/gloriosa-nct05445778"}